Key facts
- This page summarizes Peter H. Griffith's Form 4 filing for AMGEN INC (AMGN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Mar 2023, 18:10.
Peter H. Griffith - 06 Mar 2023 Form 4 Insider Report for AMGEN INC (AMGN)
- Reporting relationship
- EVP & CFO
- Issuer ticker
- AMGN
- Reported as of
- 06 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Mar 2023, 18:10:23 UTC
- Prior SEC filing
- 01 Nov 2022
- Next SEC filing
- 20 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter H. Griffith
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter H. Griffith filed Form 4 for AMGEN INC (AMGN) on 08 Mar 2023.
Change
- Previous filing in this sequence was filed on 01 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMGN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +7,753
- Change %
- +31%
- Price
- $0.000000
- Shares after
- 32,541
- Date
- 06 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares include the following RSUs granted under the Company's equity plans: 6,240 RSUs which will vest on 11/1/2023; 2,268 RSUs which will vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 3,338 RSUs which will vest in installments of 1,101 on 4/30/2023, 1,102 on 4/30/2024 and 1,135 on 4/30/202; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
Footnote F2
These shares include 1,103 DEs granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.